$BGNE Piper Jaffray Downgrades BeiGene To Neutral, Lowers Target From $230 To $165 Notes 'Post ASPEN Miss And New, Lowered Brukinsa Estimates'; Notes 'We are unsure that any of the near-term catalysts will drive shares meaningfully higher'